Cabergoline ( C b ) is a U-2 ergot derivative with a long active half-life O 4 8 h ) . In a n open rising dose study we added C b to levodopa+inhibitor in 3 0 parkinsonian patients w i t h motor fluctuations. C h m e a n daily dose w a s 13.3(6-20). given once a day. for a mean period of 1 8 . 3 16-
Clozapine in Parkinson's disease
β Scribed by Peter Gonski; P. Auzou; D. Hannequin; N. Moore
- Book ID
- 118007866
- Publisher
- The Lancet
- Year
- 1995
- Tongue
- English
- Weight
- 316 KB
- Volume
- 345
- Category
- Article
- ISSN
- 0140-6736
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Clozapine is an atypical neuroleptic medication that is free of parkinsonian side effects and that has been reported to ameliorate the tremor of Parkinson's disease. We report (with videotape illustration) the dramatic improvement of severe yet classic rest tremors in one elderly nonpsy
## Abstract The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopaβinduced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5β25 mg daily, because
## Abstract Psychosis secondary to dopaminergic therapy can limit the ability to manage motor symptoms of advanced Parkinson's disease (PD). We report the results of an open label 3βmonth trial that evaluated the antipsychotic effects of clozapine in eight PD patients with drugβinduced psychosis. R